Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Insulin (I.)Glargine Compared to NPH I. and to I. Detemir in Combination With Metformin on Prandial ß-cell Function and Overall Metabolic Control in Type 2 Diabetic Patients With Insufficient Metabolic Control During OAD Treatment

NCT00941148 is registered in ClinicalTrials.gov with ikfe-CRO GmbH as lead sponsor.

NCT NCT00941148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00941148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Insulin (I.)Glargine Compared to NPH I. and to I. Detemir in Combination With Metformin on Prandial ß-cell Function and Overall Metabolic Control in Type 2 Diabetic Patients With Insufficient Metabolic Control During OAD Treatment
Lead sponsor
ikfe-CRO GmbH
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2008
Completion date
March 31, 2009
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

insufficient metabolic control, oad treatment, type 2 diabetic patients